EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Myostatin Levels in SMA Following Disease‐Modifying Treatments: A Multi‐Center Study

Fiorella Piemonte, Sara Petrillo, Anna Capasso, Giorgia Coratti, Adele D'Amico iD, Michela Catteruccia, Maria Carmela Pera iD, Concetta Palermo, Marika Pane, Emanuela Abiusi, Gianpaolo Cicala, Marianna Villa und 12 weitere

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70070 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Fiorella Piemonte und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Myostatin, Muscular Atrophy, Spinal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study investigated myostatin levels in SMA patients receiving disease‐modifying therapies (DMTs) to understand their relationship with treatment duration and functional status.

Methods

Our study includes both cross‐sectional and longitudinal analyses of myostatin levels in treated SMA patients. The longitudinal cohort included 46 treatment‐naive patients assessed at baseline and 12 months post‐treatment. Myostatin levels were measured using ELISA. Age‐matched controls ( n = 89) were included for comparison. The cross‐sectional study included 128 patients with variable durations of treatment (from 0.4 to 7.2 years). In both cohorts, myostatin levels were correlated with SMA type, functional status, and clinical outcomes.

Results

Baseline myostatin levels were significantly lower than controls ( p < 0.001), except during the neonatal period in presymptomatic patients. After 12 months of treatment, there were no significant changes compared to baseline levels ( p = 0.1652). The only substantial changes were observed in presymptomatic neonates, who showed a reduction of myostatin despite treatment intervention. There was a significant correlation between myostatin levels, functional status, and SMA type both in the cross‐sectional and longitudinal groups.

Interpretation

This study demonstrates lower myostatin levels in SMA patients compared to controls. The association between myostatin levels, functional status, and SMA type suggests its possible role as a disease severity biomarker. The utility of myostatin as a biomarker for DMT response remains controversial; while we observed no significant increase in myostatin levels following treatment, we also did not observe the progressive reduction previously reported in untreated patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyostatinMuscular Atrophy, SpinalHumansCross-Sectional StudiesMaleFemaleChildLongitudinal StudiesChild, PreschoolInfantInfant, Newborn

Stichwörter der Autor:innen

biomarkersdisease‐modifying therapiesmyostatinneuromuscular disordersspinal muscular atrophytreatment response

Substanzen

MyostatinMSTN protein, human

Autor:innen und Institutionen

  • Department of Neurosciences, Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Pediatric Neurology Unit, Catholic University, Rome, Italy.
  • Centro Clinico Nemo, U.O.C. Neuropsichiatria Infantile, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Child Neuropsychiatry Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Section of Genomic Medicine, Department of Life Sciences and Public Health, Catholic University of Sacred Heart, Rome, Italy.
  • Department of Basic Biotechnological Sciences, Intensive Care and Perioperative Clinics, Catholic University of Sacred Heart, Rome, Italy.

ORCID-Profile: Adele D'Amico, Maria Carmela Pera, Francesco Danilo Tiziano, Stefania Corti

Förderung

  • Ministero della Salute

Zitieren

APA

Piemonte, F., Petrillo, S., Capasso, A., Coratti, G., D'Amico, A., Catteruccia, M., Pera, M. C., Palermo, C., Pane, M., Abiusi, E., Cicala, G., Villa, M., Bravetti, C., Arpaia, C., Novelli, A., Falqui, S., Fiori, S., Napoli, G., Baroni, S., …, & Mercuri, E. (2025). Myostatin Levels in SMA Following Disease‐Modifying Treatments: A Multi‐Center Study. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70070

Vancouver

Piemonte F, Petrillo S, Capasso A, Coratti G, D'Amico A, Catteruccia M, et al. Myostatin Levels in SMA Following Disease‐Modifying Treatments: A Multi‐Center Study. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70070

BibTeX
@article{Piemonte2025,
  author = {Piemonte, Fiorella and Petrillo, Sara and Capasso, Anna and Coratti, Giorgia and D'Amico, Adele and Catteruccia, Michela and Pera, Maria Carmela and Palermo, Concetta and Pane, Marika and Abiusi, Emanuela and Cicala, Gianpaolo and Villa, Marianna and Bravetti, Chiara and Arpaia, Chiara and Novelli, Agnese and Falqui, Salvatore and Fiori, Stefania and Napoli, Giulia and Baroni, Silvia and Tiziano, Francesco Danilo and Bertini, Enrico and Comi, Giacomo and Corti, Stefania and Mercuri, Eugenio},
  title = {Myostatin Levels in SMA Following Disease‐Modifying Treatments: A Multi‐Center Study},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70070}
}
Kostenlos starten →